Dendritic cells (DC) have been tested in cancer immunotherapy clinical trials for two
decades. Over this time, the methods of DC culture (or manufacture) have evolved, the …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

Dendritic cells (DCs) have shown great potential as a component or target in the landscape
of cancer immunotherapy. Different in vivo and ex vivo strategies of DC vaccine generation …

Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines,
tested different vaccine preparations, but they did not always induce sufficient acquired …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

Cancer vaccines have undergone a renaissance because of recent clinical trials showing
promising immunologic data and some clinical benefit to patients. Current trials exploiting …

Dendritic cells (DCs) are versatile elements of the immune system and are best known for
their unparalleled ability to initiate and modulate adaptive immune responses. During the …

During the last decade use of dendritic cells (DC) has moved from murine and in vitro
studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery …

Dendritic cells (DCs) are the most powerful professional antigen-presenting cells and are
unique in their capability to initiate, maintain and regulate the intensity of primary immune …